API Program

Have a Bitter Pill to Swallow?

Cough syrup being poured into a spoon

Bittermyx® BB68 Can Help.

Many active pharmaceutical ingredients (APIs) have a bitter taste, which can have a significant negative impact on patient compliance—especially in pediatric and geriatric patient populations. Due to difficulties in swallowing coated or encapsulated forms of the API, these patients are more often given prescriptions in syrup or liquid suspension formats where the bitter taste of the API may be more prevalent and problematic.

Our innovative product Bittermyx BB68 is effective against a wide range of bitter-tasting ingredients, both active and inactive, and can help improve taste without sacrificing efficacy or adding unnecessary sugar or other flavors in end product applications. BB68 improves the overall taste of certain over-the-counter (OTC) and pharmaceutical products, including capsules, lozenges, tablets, dry and liquid formulations and oral care products. For example, BB68 can help attenuate the bitter taste of commonly used APIs such as acetaminophen, dextromethorphan, guaifenesin and esomeprazole.

Download a BB68 Product Sheet
Senomyx has established a broker relationship with Austin Chemical to support sales of Bittermyx BB68 to the pharmaceutical industry.

Click here to visit their site

22 and You

Salt Taste Research

Discover the Perfect Solution for Your Product’s Bitterness

Senomyx now offers a customized, fee-for-service bitter blocking program to pharmaceutical companies for APIs and excipients to provide effective solutions for your unique bitterness challenges.

Our scientists have identified the function of 22 bitter taste receptors responsible for sending the bitter taste signals in many API products used in OTC and prescription drugs. Leveraging this knowledge, Senomyx has developed a comprehensive bitter receptor profile to more effectively screen APIs and to identify the specific bitter receptors associated with bitter taste of a given API.

Pharmaceutical companies can submit their APIs for bitter profile screening and can subsequently evaluate the efficacy of using Bittermyx BB68 or potentially another Senomyx bitter blocker development candidate for blocking inherent product bitterness.

Typical Bitter Receptor Profile Screening Project Outline:

Phase I: Provide small quantity of APIs to support screening activity for each API of interest; the specific receptor(s) responsible for bitter taste will be determined

Phase II: Generate dose response curve for selected APIs

Phase III: Determine proprietary antagonists to block bitterness

  • Test API + blocker for each receptor identified
  • Senomyx will determine the mechanism of action for the selected antagonist / API pairings

Phase IV: Test bitter blocker (antagonist) in taste trials

  • Customer will receive sample of bitter blocker under Material Transfer Agreement to test in formulations based on the data and results in Phases I – III

Contact SNMX for more information